NCT04495322View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

November 26, 2020

Study Completion Date

December 30, 2020

Conditions
Healthy Chinese Volunteers
Interventions
DRUG

TG-1000

Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

DRUG

Placebo

Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.

Trial Locations (1)

Unknown

Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

TaiGen Biotechnology Co., Ltd.

INDUSTRY

NCT04495322 - To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers. | Biotech Hunter | Biotech Hunter